M
Power Law company profile
Moderna Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2010 · IPO 2018 Decacorn
Valuation
$14B
Market cap · Apr/2026
Revenue
$1.92B
Latest reported FY
Global footprint
Where Moderna Therapeutics has talent and traffic
AI talent share
0.9%
of workforce is AI talent
(57 of 6,307 staff)
(57 of 6,307 staff)
Core AI150.24%
Other AI420.67%
Non-AI workforce6,25099.1%
Web traffic by country
180K
monthly visits
across markets
across markets
🇺🇸 United States54.9%
🇬🇧 United Kingdom4.4%
🇨🇦 Canada4.2%
🇯🇵 Japan3.9%
🏳️ Korea3.1%
Patent intelligence
$258M patent portfolio · 259 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$258M
1.9% of market cap · 3× smaller than top peer BioNTech ($780M)
259 active patent families
Where Moderna Therapeutics innovates
Molecular biologyPolynucleotideNucleic acidCell biologyRNA
Below peer median on Market
Quality vs same-sector peers
Moderna Therapeutics on the five Patsnap quality dimensions
Moderna Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Moderna Therapeutics concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Moderna Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Moderna Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.